News for Healthier Living

ESMO: Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

September 13, 2024


September 15 2024

September 14 2024

September 13 2024

September 12 2024

September 11 2024

September 10 2024

September 9 2024

September 8 2024

September 7 2024

September 6 2024

September 5 2024

September 4 2024

September 3 2024

September 2 2024